RT-301 is under clinical development by Suzhou Ruotai Pharmaceutical Technology and currently in Phase I for Unspecified Infectious Diseases. According to GlobalData, Phase I drugs for Unspecified Infectious Diseases does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RT-301 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RT-301 overview
Suzhou Ruotai Pharmaceutical Technology overview
Suzhou Ruotai Pharmaceutical Technology is engaged in the research and development of chemicals, pharmaceuticals and intermediates. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of RT-301’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.